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Abstract (250 words) 
Purpose: Inequalities in the burden of cancer have been well-documented and a variety of measures exist to 
analyse disease disparities. While previous studies have focused on inequalities within countries, the aim of 
the present study was to quantify existing inequalities in cancer incidence and mortality between countries.  
Methods: Data on total and site-specific cancer incidence and mortality in 2003-2007 were obtained for 43 
countries with medium to high levels of human development via Cancer Incidence in Five Continents Vol. X 
and the WHO Mortality Database. We calculated the concentration index as a summary measure of 
socioeconomic-related inequality between countries. 
Results: Inequalities in cancer burden differed markedly by site; the concentration index for all sites combined 
was 0.03 for incidence and 0.02 for mortality, pointing towards a slightly higher burden in countries with 
higher levels of the Human Development Index (HDI). For both incidence and mortality, this pattern was most 
pronounced for melanoma. In contrast, the burden of cervical cancer was disproportionally high in countries 
with lower HDI levels. Prostate, lung and breast cancer contributed most to inequalities in overall cancer 
incidence in countries with higher HDI levels, while for mortality these were mostly driven by lung cancer in 
higher HDI countries and stomach cancer in countries with lower HDI levels. 
Conclusion: Global inequalities in the burden of cancer remain evident at the beginning of the 21st century: 
with a disproportionate burden of lifestyle-related cancers in countries classified as high HDI, while infection-
related cancers continue to predominate in transitioning countries with lower levels of HDI. 
 
 





Cancer cases and deaths are not equally distributed across populations. In 2012, more than half of all new 
cancer cases and two thirds of all cancer deaths occurred in less developed regions. (1) Although differences 
may be partly attributed to demographic structure, population size and stages of epidemiologic transition, 
much of the observed disparities remain unexplained. (2, 3) It therefore remains open to discussion whether 
these inequalities are avoidable. 
Quantifying, understanding and reducing inequalities has become a strategic priority in global policy making 
and represents one of the 17 sustainable development goals released by the United Nations. (3) Previous 
studies have documented the degree to which inequalities in the burden of disease and mortality are linked to 
socioeconomic status within countries or regions. (4, 5) In view of the rising burden of cancer worldwide and 
on-going changes in cancer patterns and profiles across human development levels, it is equally important to 
gain further insights into the distribution of cancer cases and deaths across levels of human development as an 
indication of between country inequalities (6). Yet, this knowledge remains scarce and a global quantification 
of inequalities in cancer burden is still lacking. 
Therefore in this study, we aimed to quantify and assess inequalities in site-specific cancer burden across 43 
countries (from medium to high HDI level countries determined by data availability). By linking the human 
development index (HDI) (7) with cancer incidence and mortality, we were able to compute the concentration 







Data on cancer incidence between 2003 and 2007 were extracted from Cancer Incidence in Five Continents 
Volume X (CI5X). (8) These are the most recent data from high-quality population-based cancer registries, with 
detailed assessment of the comparability, completeness, and validity. Data from national registries were 
available for the majority of countries (25 countries). If nationwide data were absent, cases from regional 
registries in the same country were pooled to obtain an estimate of the national incident cancer burden (18 
countries). Data on cancer mortality were obtained from the WHO Mortality Database for the years 2003-
2007. (9) To ensure data quality, we only included data from countries where previous data quality 
assessments indicated at least medium quality data. (10) For mortality, all datasets represented a nationwide 
registration of cancer deaths by cause. For both incidence and mortality, the following most commonly 
diagnosed cancer sites were included: all sites excluding non-melanoma skin (ICD-10:C00-96 excl. C44), 
oesophagus (C15), stomach (C16), colorectum (C18-21), pancreas (C25), trachea, bronchus and lung (C33-34), 
melanoma of skin (C43), female breast (C50), cervix uteri (C53), prostate (C61), kidney (64) and leukaemia 
(C91-95). In addition, cancers of the head and neck (C00-14) and testis (C62) were included because of their 
known or suspected link with socioeconomic status (11, 12).  
Population data by country, sex and age were obtained from the United Nations (UN), world population 
prospects, for the year 2005. (13) Estimates of HDI and its components (life expectancy, education and gross 
domestic product (GDP) per capita ) by country for the year 2005 were available from the United Nations 
Development Programme. (7) Age-standardized incidence and mortality rates were calculated using the world 
standard population. In this study, we included countries where both good quality incidence and mortality 
data were available, resulting in a total of 43 medium to highly developed countries with an HDI ranging from 
0.771 (the Philippines) to 0.968 (Iceland and Norway) (Annex Table 1).  
Statistical analysis 
In order to assess inequality in the burden of cancer across levels of human development, we first compared 
the overall population size to the number of cases or deaths by cancer site for each tertile of HDI. In a second 
step, concentration curves were drawn and concentration indices calculated by cancer site for incidence and 
mortality. (14) 
The concentration curve provides a graphical representation of inequality. It plots the cumulative cancer 
incidence or mortality rate against the cumulative proportion of the population ranked by each country’s HDI 
(from lowest to highest, left to right). When it coincides with the diagonal, the line of perfect equality, there is 
no association between the incidence or mortality rates across countries and HDI. In contrast, the further the 
curve lies above (or below) the diagonal, the greater the concentration of cases among those countries with 
lower (or higher) levels of HDI. 
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The concentration index is directly related to the concentration curve and provides a summary measure of the 
deviation from the line of perfect equality. It has been developed by health economists, [10] and used to 
measure and compare the degree of socioeconomic inequality, for instance in child mortality (15), adult health 
(16), access to health care (17) or lifestyle factors such as physical activity or obesity. (18) It is closely related to 
the relative index of inequality, (19) and proportional to the association between each country’s share in the 
total cancer burden and the population-weighted rank of human development (20). 
The concentration index ranges from -1 to 1. (14, 21) It takes a value of zero if the concentration curve 
coincides with the diagonal or if the concentration of cases among countries with lower levels of HDI is equal 
to the concentration of cases among countries with higher HDI levels (in which case the curve is not equal to 
the line of perfect inequality). A concentration index greater than zero indicates that the cancer cases or 
deaths are disproportionally concentrated in higher HDI countries (the concentration curve lies below the 
diagonal), while a value below zero points towards a higher burden in countries with lower levels of HDI (the 
concentration curve lies above the diagonal). Point estimates, standard errors and corresponding 95% 
confidence intervals for the concentration index were computed using the conindex, and existing command 
from the statistical software package Stata. (20) As the concentration index is a function of the covariance of 
HDI rank and incidence or mortality shares, it can easily be decomposed into the contributions of each cancer 
site to the overall inequalities. The contribution of each cancer site consists of the product of the HDI-related 
inequality in this cancer site and its weight in the total of cancer cases and deaths. (22, 23)  
As patterns were similar for males and females, no sex-specific results (except for sex-specific tumours) were 







Overall, the number of new cancer cases was more concentrated in countries with higher levels of HDI. 
Countries within the highest HDI tertile had a slightly higher burden of all cancer sites combined; together they 
accounted for 44% of all cancer cases but only for 42% the total population considered (Figure 1). In contrast, 
countries in the lowest HDI tertile accounted for 34% of all cancer cases and comprised 37% of the total 
population. There was marked disparity for melanoma (60% of burden in highest vs. 18% in lowest HDI tertile), 
cancer of the bladder (50% vs. 23%), prostate (54% vs. 28%), lung (51% vs. 28%), testis (52% vs. 16%), kidney 
(55% vs. 18%), breast (48% vs. 31%), pancreas (46% vs. 32%), colorectum (45% vs. 32%) and leukaemia (46% 
vs. 33%). Conversely, countries within the lowest HDI tertile had a disproportionate burden of cervical (55% of 
burden in lowest vs. 28% in highest HDI tertile) cancer cases. 
When summarizing this inequality for all cancer sites combined, the concentration index (C) was 0.03 (95%CI: 
0.00, 0.06), pointing towards a slightly higher incidence burden in countries with higher HDI levels (Figure 2). 
This pattern was most pronounced for melanoma (C: 0.23; 95%CI: 0.11, 0.35), as well as for cancers of the 
bladder, prostate, lung, testis, kidney, breast, pancreas and colorectum, and leukaemia. The high burden of 
cervical cancer in countries with lower HDI levels was also confirmed using the concentration index (C: -0.21; 
95%CI: -0.25, -0.17) and apparent in the concentration curve. Inequalities in incident cancer burden across HDI 
levels were statistically non-significant for cancers of the head and neck, oesophagus, stomach, and liver. 
Table 1 also provides the results of the decomposition analysis, which quantifies each cancer site’s 
contribution to the inequality in cancer incidence of all sites combined. According to this analysis, prostate, 
lung and breast cancer contribute most to the incident cancer burden in countries with high HDI levels, while 
cervical cancer contributed most to the cancer burden in countries with lower levels of HDI. Interestingly, the 
contribution of cervical cancer was much smaller in absolute value because its smaller weight in the total of 
cancer cases – despite being much more unequally distributed than lung, breast and prostate cancer. 
Cancer mortality 
Although overall cancer deaths were more equally distributed across HDI tertiles than incident cancer cases, 
this varied considerably by cancer site (Figure 1). While deaths from melanoma (50% of burden in highest vs. 
28% in lowest HDI tertile), cancer of the pancreas (48% vs. 29%), lung (51% vs. 28%) and kidney (54% vs. 19%) 
as well as colorectum (44% vs. 33%), bladder (44% vs. 32%) and oesophagus (44% vs. 35%) were 
disproportionally higher in countries within the highest HDI tertile, the opposite was true for cancers of the 
cervix (23% vs. 62%), head and neck (32% vs. 50%), stomach (29% vs. 49%), and testis (38% vs. 39%). More 
than 60% of all cervical cancer deaths occurred in countries within the lowest HDI tertile, with an aggregated 
population comprising 38% of the total.
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index (C)* 95%CI p-value Weight§ contribution** 
Concentration 
index (C)* 95%CI p-value Weight§ contribution** 
All sites (C00-97, but C44) 0.03 (0.00,0.06) 0.05   0.02 (-0.00,0.05) 0.06   
Head & Neck (C00-14) -0.04 (-0.09,0.02) 0.18 0.03 -0.001 -0.13 (-0.19,-0.08) 0.00 0.03 -0.003 
Oesophagus (C15) 0.05 (-0.02,0.12) 0.16 0.01 0.001 0.05 (-0.01,0.11) 0.09 0.03 0.001 
Stomach (C16) -0.01 (-0.15,0.12) 0.85 0.05 -0.001 -0.11 (-0.22,0.01) 0.08 0.07 -0.008 
Colorectum (C18-21) 0.06 (0.04,0.09) 0.00 0.10 0.007 0.06 (0.01,0.10) 0.03 0.10 0.006 
Liver (C22) # 0.03 (-0.12,0.18) 0.73 0.02 0.001 -0.04 (-0.16,0.09) 0.58 0.04 -0.002 
Pancreas (C25) 0.07 (0.03,0.10) 0.00 0.02 0.001 0.11 (0.07,0.14) 0.00 0.05 0.005 
Lung (C34) 0.10 (0.06,0.14) 0.00 0.10 0.010 0.10 (0.06,0.15) 0.00 0.21 0.022 
Melanoma (C43) 0.23 (0.11,0.35) 0.00 0.03 0.006 0.12 (0.03,0.22) 0.01 0.01 0.001 
Breast (C50) 0.07 (0.02,0.12) 0.00 0.12 0.009 0.01 (-0.03,0.05) 0.70 0.07 0.001 
Cervix (C53) -0.21 (-0.25,-0.17) 0.00 0.02 -0.004 -0.26 (-0.33,-0.20) 0.00 0.01 -0.004 
Prostate (C61) 0.11 (0.03,0.19) 0.01 0.12 0.013 -0.01 (-0.07,0.04) 0.59 0.05 -0.001 
Testis (C62) # 0.10 (-0.00,0.20) 0.06 0.01 0.001 -0.11 (-0.21,-0.00) 0.05 0.00 0.000 
Kidney (C64-66) # 0.09 (0.02,0.16) 0.01 0.02 0.002 0.09 (0.02,0.16) 0.02 0.02 0.001 
Bladder (C67) 0.12 (0.05,0.19) 0.00 0.03 0.004 0.06 (-0.00,0.12) 0.07 0.02 0.001 
Leukemia(C91-95) 0.04 (0.01,0.07) 0.01 0.03 0.001 0.01 (-0.01,0.04) 0.34 0.03 0.000 
* The concentration index (C) provides a summary measure of the deviation from the line of perfect equality (as shown in the concentration curves in Figure 2). C=0 indicates that the concentration of cases among 
countries with lower levels of HDI is equal to the concentration of cases among countries with higher HDI levels (=equality); C>0 indicates that cancer cases/deaths are disproportionally concentrated in high HDI 
countries (the concentration curve lies below the diagonal); C<0 indicates that cancer cases/deaths are disproportionally concentrated in countries with lower HDI countries (the concentration curve lies above the 
diagonal). 
§ Weight equals the population weighted incidence/mortality rate of each cancer site. 
**Contribution quantifies the contribution of each cancer site listed in the table, to the overall inequality of all-sites combined (C00-97 but C44). It is obtained as the concentration index multiplied by weight divided 
by the overall incidence or mortality rate (see Methods). 
#does not include data from Russia, Belarus, Ukraine and Switzerland  
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Concentration curves of cancer mortality were on average slightly closer to the line of perfect equality when 
compared to cancer incidence (Figure 2). While for all sites combined, the concentration index for mortality 
was very similar to that of cancer incidence, the countries with higher HDI levels were disproportionally 
affected by melanoma (C: 0.12; 95%CI: 0.03, 0.22), followed by cancer of the pancreas, lung, kidney, 
colorectum, bladder, and oesophagus. A disproportionally higher mortality in countries with lower HDI levels 
was most pronounced for cervical cancer (C: -0.26; 95%CI: -0.33, -0.20), but was also found for cancers of the 
head and neck, stomach and testis.  
When the inequality in cancer mortality from all sites combined was decomposed into each cancer site’s 
contribution, lung cancer was the main contributor to the cancer mortality burden in countries with higher HDI 
levels, while stomach cancer contributed most to corresponding inequalities in countries with lower HDI levels 
(Table 1). This reinforces the observation – as can be seen on comparison of the concentration indices for 
cancers of the cervix and stomach – that the site-specific contribution depends on the weight of total deaths 





This is the first investigation and visual representation of how inequalities in the cancer burden in the 21st 
century relate to human development. Marked inequalities in the cancer burden were found for both 
incidence and mortality; with differences across cancer sites. Whereas the burden from cancers such as 
prostate, breast and lung cancer was greater in countries with higher HDI levels and thus contributed most to 
overall inequalities in cancer incidence, cancer of the cervix represented a disproportionate burden in 
countries with lower HDI levels. Lung and stomach cancer were the main drivers of overall inequalities in 
cancer mortality in high and medium HDI countries. While previous studies have reported similar patterns (6, 
24), our study confirmed and quantified these inequalities using the concentration index across a large number 
of countries internationally. 
Lifestyle-related cancers represented the largest source of inequality in cancer incidence. Inequalities in kidney 
and lung cancer are likely related to past smoking patterns that translated into a high burden of smoking-
related cancers in countries with higher HDI levels due to a long lag-time. In view of the shifting smoking 
epidemic towards an increasing prevalence in lower HDI countries (25, 26), inequalities in the burden of 
smoking-related cancers are likely to even out in the coming decades. Similar trends also apply to risk factors 
such as obesity and alcohol consumption, as well as diet and reproductive factors, which are assumed to be 
the main drivers of inequalities in lifestyle-related cancers in high HDI countries. Another cancer that was 
largely disproportionate in high HDI countries was Melanoma.  It has been known to affect primarily fair-
skinned, Caucasian populations and more highly developed countries. (27) Similarly, testicular cancer is much 
more common in countries with a high or very high HDI, with ongoing increases in incidence that largely 
remain unexplained. (28) 
Lower socio-economic position has previously been linked to an increased risk of acquiring infection with 
human papillomavirus (HPV), helicobacter pylori (H pylori) and hepatitis B/C virus (29, 30), the main infectious 
agents that are linked to cancer. Also, the vast majority (80%) of all infection-related cancers occur in less 
developed regions of the world. (31) High-risk HPV types are considered a necessary cause for cervical cancer 
and accounted for half of all cancer cases attributable to infection in women in 2008. (31, 32) In addition, 
recent evidence suggested that about 89% of all (non-cardia) stomach cancers are attributable to H pylori. (33) 
In accordance with this, we found a disproportionate burden of cervical cancer incidence and mortality and 
stomach cancer mortality in lower HDI countries. Most notably, 55% of all new cervical cancer cases and more 
than 60% of cervical cancer deaths occurred in countries within the lowest HDI quartile, while accounting for 
only 38% of the total population considered. This points towards greater inequality in cancer mortality than in 
incidence for infection-related cancers and is in accordance with recent evidence suggesting that stomach and 
cervical cancer contributed most to disability-adjusted life-years lost from cancer and represent important 
causes of premature mortality in lower HDI regions. (34).  
The incident burden of breast cancer was greater in countries with high HDI levels, which is probably related to 
lifestyle and reproductive factors, but might also reflect the impact of more active early detection of breast 
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cancer and differences in access to diagnostic services. In contrast, relative to the number of newly diagnosed 
breast cancers, fewer breast cancer deaths occurred in countries with high HDI levels. Differences between 
inequalities in cancer incidence and mortality might thus point towards differences in access to medical 
services and cancer treatment centres. Even within Europe, standards of care differ greatly between countries 
and variation in cancer survival has been associated with national wealth, investments in health technology 
and education. (35-37) In this study, in general we saw that in countries with higher HDI levels the proportion 
of new cancer cases was equal or greater than the proportion of cancer deaths from all included cancer sites. 
On the contrary the reverse was true for countries with lower HDI levels. This was particularly pronounced for 
testicular cancer, with 32% of all deaths but only 13% of all incident cases occurring in countries with lower 
HDI levels, but also true for other cancer sites such as cancer of the head and neck, stomach, liver, breast, 
prostate, bladder and melanoma.  
In this study, the most comprehensive, available and high quality data on cancer incidence and mortality were 
used, coming from two different sources. The selection criteria for incidence and mortality data restricted the 
final dataset to 43 countries. Our applied method, the concentration index, has the advantage of not only 
using information from the full HDI spectrum and accounting for population sizes of the set of countries 
included in the study, but also enabling the graphical depiction of inequality using the concentration curve. 
Despite this, the lack of data from low HDI settings and the data quality requirements for inclusion in this study 
led to an overrepresentation of highly developed countries. The results presented are thus predominantly 
relevant to high and very high HDI countries (see Annex Table 1) and are subject to some change were other 
datasets available and included. Restricting the analysis to only (very) high HDI countries, i.e. excluding 
Colombia, Ukraine and the Philippines, did not substantially alter the results and suggests that our findings also 
hold across high HDI countries. Including a larger set of countries, especially those of low and medium HDI, 
would assign more weight to these populations. This, in turn, might further emphasize inequalities in the 
burden of cancers that are more common in low HDI countries, notably infection- and poverty-related cancers.  
Inequalities in cancer burden can be measured on different levels, using different indicators. The choice of the 
metric for quantifying inequalities can potentially lead to different results. (38) Using the current approach, we 
assessed inequalities in cancer incidence and mortality across HDI ranks – and not inequality per se. We 
repeated these analyses with the different components of HDI, i.e. education, life expectancy and gross 
domestic product, as rank measures and the results were very similar. On the other hand, summarizing the 
degree of inequality in a single number, the concentration index, enabled us to directly compare the degree of 
inequality across cancer sites. That the concentration index and curve can also be  good temporal indicators of 
changes in disparities has previously been shown for breast cancer incidence and mortality in the United 
States. (39) Repeating and updating these analyses on the global level could potentially reveal important clues 
about transitions in disparities. Together with its visual representation, the concentration index offers a 
possibility to quantify inequalities and to identify the exact location of deviations from proportionality. By 
calculating the concentration index based on aggregated, country-level data (and not individual-level data), 
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within-country inequalities and regional variability were not considered; this analysis was beyond the scope of 
this work, while individual-level data are available in only a few countries.  
Our study has shown that inequalities in the burden of cancer remain evident in the 21st century, even across 
medium to high HDI countries, and can be characterized by a disproportionate burden of lifestyle-related 
cancers in high HDI and infection-related cancers in lower HDI countries. Reducing the cancer burden from 
largely preventable and treatable cancers that are closely interrelated with inequalities must be priorities in 
cancer control. Yet, inequalities remain complex, require surveillance over time and must be used 
synergistically with other measures, including those that proxy within-country inequality. In future studies, 
incorporating data from countries undergoing developmental transition will be vital to better map global 
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Figure 1. Proportion of cancer cases (inc), deaths (mort) and population (pop) by HDI tertile and cancer site 
*results for kidney, liver and testicular cancer do not include data from Russia, Belarus, Ukraine and 
Switzerland 
 
Figure 2. Concentration curves and indices for site-specific cancer incidence and mortality using HDI as ranking 
variable * 
*results for kidney, liver and testicular cancer do not include data from Russia, Belarus, Ukraine and 
Switzerland 
The concentration index (C) provides a summary measure of the deviation from the line of perfect equality as indicated by the 
concentration curves. C=0 indicates that the concentration of cases among countries with lower levels of HDI is equal to the concentration 
of cases among countries with higher HDI levels (=equality); C>0 indicates that cancer cases/deaths are disproportionally concentrated in 
high HDI countries (the concentration curve lies below the diagonal); C<0 indicates that cancer cases/deaths are disproportionally 
concentrated in countries with lower HDI countries (the concentration curve lies above the diagonal) 
   


